Clínic Barcelona

A new treatment reduced much more than any other the symptoms of myelofibrosis

Myelofibrosis is a rare spontaneous disease that affects bone marrow progenitor cells. In 2005 researchers discovered that 60% of patients carry an acquired mutation of JAK2 gene in blood cells. The disease is characterized by a progressive replacement of bone marrow with fibrosis, which prevents the proper production of blood cells. Symptoms are heterogeneous and affect deeply the quality of life of people who suffer it. The most common are anemia, weight loss, excessive sweating accentuated at night and abdominal discomfort due to spleen enlargement. Moreover, in some cases myelofibrosis may evolve to an acute leukemia. An article in New England Journal of Medicine (NEJM) compares the best treatment available so far for myelofibrosis with ruxolitinib, a new therapy that has proven far more effective. Dr. Francisco Cervantes, from the Hematology Service of Hospital Clínic of Barcelona and team leader of the Institut Biomedical Research August Pi i Sunyer (IDIBAPS) Hematological oncology group, is one of the authors of the work that will change the treatment of this disease.